GENMAB A/S -SP ADR
GMABNASDAQUS Equity
$30.82▼ $0.06 (−0.18%)
Market closed · at close1h—
24h▼ 0.2%
7d—
14d—
30d—
1y—
🏦Market Cap
$1.92B
Small Cap
📈Revenue Growth (YoY)
+20.7%
Healthy
📊Gross Margin
93.3%
High
💵FCF Margin
29.0%
Strong
⚖️P/S Ratio
4.7x
Fair
Otter Score
56
Weak
No chart data available for GMAB.
Trading Snapshot
- Day Range
- $30.33 – $31.20
- 52-Week Range
- $1,337.00 – $2,257.00
- Volume
- $4.02B
- Avg Volume
- $4.49B
- Shares Outstanding
- 62.4M
- Next Earnings
- Sep 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $278M
- Last Q Revenue
- $63M
- P/E Ratio
- 22.5
- P/S Ratio
- 4.7x
- EPS (TTM)
- $13.20
- Dividend Yield
- —
Why Investors Own GMAB
- ✓High-growth profile — revenue up +13.4% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 8% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$278M▲ +17.6% YoY
Gross Margin (TTM)
55.9%▼ −0.5% YoY
Operating Income (TTM)
$104M▲ +17.6% YoY
Free Cash Flow (TTM)
$22M▲ +17.6% YoY
About GENMAB A/S -SP ADR
A company profile for GENMAB A/S -SP ADR isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
56/100
Analyst Price Target
ⓘAverage Target
$31.12
▲ +1.0% Upside
High Target$36.57
Low Target$26.57
Based on 21 analysts
Latest News & Updates
🚀
Reuters·2h ago
GENMAB A/S -SP ADR tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Barron’s·5h ago
Analysts lift GMAB price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
MarketWatch·1d ago
GENMAB A/S -SP ADR announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.